Harbor Capital Advisors’s LENZ Therapeutics LENZ Stock Holding History

Harbor Capital Advisors’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$92K	Buy	16,284 +2,375	+17%	+$19.1K	0.01%	657
2026 Q1	$127K	Sell	13,909 -10,012	-42%	-$141K	0.01%	622
2025 Q4	$383K	Buy	23,921 +9,316	+64%	+$272K	0.03%	551
2025 Q3	$680K	Sell	14,605 -35,436	-71%	-$1.3M	0.05%	401
2025 Q2	$1.47M	Buy	50,041 +1,425	+3%	+$38.8K	0.06%	375
2025 Q1	$1.25M	Buy	48,616 +4,627	+11%	+$114K	0.06%	389
2024 Q4	$1.27M	Buy	+43,989	New	+$1.34M	0.06%	408

Other funds holding LENZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

KBC Group Brussels, Belgium $46.3B AUM 43.9% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Harbor Capital Advisors's LENZ Position: Q2 2026 in Review

Harbor Capital Advisors increased its LENZ Therapeutics (LENZ) stake by 17% in Q2 2026, buying an estimated $19.1K and bringing the position to 16,284 shares worth $92K. The position accounts for 0.01% of the portfolio, ranked #657.

Harbor Capital Advisors first reported a position in LENZ in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.47M in Q2 2025. 53 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

Harbor Capital Advisors held 16,284 shares of LENZ Therapeutics worth $92K as of Q2 2026.
Harbor Capital Advisors bought 2,375 LENZ Therapeutics shares in Q2 2026, an estimated $19.1K.
LENZ Therapeutics made up 0.01% of Harbor Capital Advisors's portfolio in Q2 2026, its #657 holding.
Harbor Capital Advisors first reported a position in LENZ Therapeutics in Q4 2024 and has held it in 7 quarters since.
Harbor Capital Advisors's LENZ Therapeutics position peaked at $1.47M in Q2 2025.
53 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on Harbor Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.